Show simple item record

dc.contributor.authorRyan, Paul M
dc.contributor.authorStanton, Catherine
dc.contributor.authorCaplice, Noel M
dc.date.accessioned2018-01-11T10:03:30Z
dc.date.available2018-01-11T10:03:30Z
dc.date.issued2017-12-28
dc.identifier.citationRyan PM, Stanton C, Caplice NM. Bile acids at the cross-roads of gut microbiome–host cardiometabolic interactions. Diabetology & Metabolic Syndrome 2017;9(1):102; doi 10.1186/s13098-017-0299-9.en_GB
dc.identifier.urihttp://hdl.handle.net/11019/1529
dc.descriptionpeer-revieweden_GB
dc.descriptionThis work is supported in part by the APC Microbiome Institute (under Science Foundation Ireland [SFI] Grant Number: SFI/12/RC/2273) and by Enterprise Ireland Commercialization Fund (Contract Reference: CF/2013/3030A/B).
dc.description.abstractWhile basic and clinical research over the last several decades has recognized a number of modifiable risk factors associated with cardiometabolic disease progression, additional and alternative biological perspectives may offer novel targets for prevention and treatment of this disease set. There is mounting preclinical and emerging clinical evidence indicating that the mass of metabolically diverse microorganisms which inhabit the human gastrointestinal tract may be implicated in initiation and modulation of cardiovascular and metabolic disease outcomes. The following review will discuss this gut microbiome–host metabolism axis and address newly proposed bile-mediated signaling pathways through which dysregulation of this homeostatic axis may influence host cardiovascular risk. With a central focus on the major nuclear and membrane-bound bile acid receptor ligands, we aim to review the putative impact of microbial bile acid modification on several major phenotypes of metabolic syndrome, from obesity to heart failure. Finally, attempting to synthesize several separate but complementary hypotheses, we will review current directions in preclinical and clinical investigation in this evolving field.en_GB
dc.description.sponsorshipScience Foundation Irelanden_GB
dc.description.sponsorshipEnterprise Ireland
dc.language.isoenen_GB
dc.publisherBiomed Centralen_GB
dc.relation.ispartofseriesDiabetology & Metabolic Syndrome;
dc.subjectMicrobiome –en_GB
dc.subjectBile acidsen_GB
dc.subjectCardiovascular diseaseen_GB
dc.subjectMetabolic syndromeen_GB
dc.titleBile acids at the cross-roads of gut microbiome–host cardiometabolic interactionsen_GB
dc.typeArticleen_GB
dc.date.updated2017-12-31T04:18:05Z
dc.language.rfc3066en
dc.rights.holderThe Author(s)
dc.identifier.doihttp://dx.doi.org/10.1186/s13098-017-0299-9
dc.contributor.sponsorScience Foundation Ireland
dc.contributor.sponsorEnterprise Ireland Commercialization Fund
dc.contributor.sponsorGrantNumberSFI/12/RC/2273
dc.contributor.sponsorGrantNumberCF/2013/3030A/B
refterms.dateFOA2018-01-12T08:57:49Z


Files in this item

Thumbnail
Name:
13098_2017_Article_299.pdf
Size:
991.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record